Equity Overview
Price & Market Data
Price: $28.08
Daily Change: -$5.19 / 18.48%
Daily Range: $28.08 - $28.08
Market Cap: $3,209,187,584
Daily Volume: 10
Performance Metrics
1 Week: -15.60%
1 Month: -15.60%
3 Months: -11.36%
6 Months: -16.05%
1 Year: 25.41%
YTD: -11.36%
Company Details
Employees: 452
Sector: Health technology
Industry: Biotechnology
Country: Belgium
Details
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.